If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Kerry-Lynne Donna Findlay (born January 12, 1955) is a Canadian politician and lawyer who served as leader of the Conservative Party of British Columbia from May to September 2026. She had served as a member of Parliament (MP) for South Surrey—White Rock from 2019 to 2025 and Delta—Richmond East from 2011 to 2015 with the federal Conservative Party. Findlay was Associate Minister of National Defence in 2013, and Minister of National Revenue from 2013 to 2015 under Prime Minister Stephen Harper.
Even after the 1947 partition, the Muslims from India kept migrating to Pakistan, especially Karachi and Sindh province. Wars in neighbouring Afghanistan in the 1980s and 1990s pushed millions of Afghan refugees into Pakistan, mainly in Khyber-Pakhtunkhwa and tribal areas, with some in Karachi and Quetta. Pakistan hosts one of the world's largest refugee populations. Additionally, around 2 million Bengalis and half a million undocumented individuals, purportedly from Myanmar, reside in Pakistan. Pakistan ordered the mass expulsion of undocumented Afghans in October 2023, citing national security risks. Migration of Bengalis and Rohingya to Pakistan started in the 1980s and continued till 1998. Karachi hosts a significant number of Bengali settlements, and large Rohingya migration made it one of their largest populations outside Myanmar. Karachi's Burmese community resides in various slums across the city. According to BBC, thousands of Uyghur Muslims live in Gilgit-Baltistan, some left Xinjiang, China and the thriving trading town of Kashgar in 1949, while others are later arrivals, claiming to escape political oppression. Since 1989, thousands of Kashmiri Muslim refugees fled to Pakistan, alleging rape and forced displacement by Indian soldiers.
=== Paradoxical effects === Flunitrazepam may cause a paradoxical reaction in some individuals, including anxiety, aggressiveness, agitation, confusion, disinhibition, loss of impulse control, talkativeness, violent behavior, and even convulsions. Paradoxical adverse effects may even lead to criminal behaviour.
Sources: en.wikipedia.org
Mitochondrial branched-chain amino acid aminotransferases are the more ubiquitous of the two isoforms, present in all tissues in the mitochondria of the cell. Pancreatic acinar tissue has been found to carry the highest levels of BCATm in the body In addition, two homologs to normal BCATm have been found. One homolog is found in placental tissue, and the other co-represses thyroid hormone nuclear receptors. BCATm is more sensitive to the redox environment of the cell, and can be inhibited by nickel ions even if the environment is reducing. BCATm has been found to form no disulfide bonds, and titration of two -SH groups with 5,5'- dithiobis(2-nitrobenzoic acid) eliminates enzyme activity completely in the case of the BCATm isozyme. In humans, BCATm is encoded by the BCAT2 gene.
In the eastern United States in the early 2000s, sulfate particles were estimated to account for 25% or more of all air pollution. Exposure to sulfur dioxide emissions by coal power plants (coal PM2.5) in the US was associated with 2.1 times greater mortality risk than exposure to PM2.5 from all sources. Meanwhile, the Southern Hemisphere had much lower concentrations due to being much less densely populated, with an estimated 90% of the human population in the north. In the early 1990s, anthropogenic sulfur dominated in the Northern Hemisphere, where only 16% of annual sulfur emissions were natural, yet amounted for less than half of the emissions in the Southern Hemisphere.
Dial up Dial down Pendant up Pendant down Pendant left Pendant right Temperature (from 34 to 100 degrees Fahrenheit (1 to 38 °C)) Isochronism (the ability of the watch to keep time, regardless of the mainspring's level of tension) Positional adjustments are attained by careful poising (ensuring even weight distribution) of the balance-hairspring system as well as careful control of the shape and polish on the balance pivots. All of this achieves an equalization of the effect of gravity on the watch in various positions. Positional adjustments are achieved through careful adjustment of each of these factors, provided by repeated trials on a timing machine. Thus, adjusting a watch to position requires many hours of labor, increasing the cost of the watch. Medium grade watches were commonly adjusted to 3 positions (dial up, dial down, pendant up) while high grade watches were commonly adjusted to 5 positions (dial up, dial down, stem up, stem left, stem right) or even all 6 positions. Railroad watches were required, after 1908, to be adjusted to 5 positions. 3 positions were the general requirement before that time. Early watches used a solid steel balance. As temperature increased, the solid balance expanded in size, changing the moment of inertia and changing the timing of the watch. In addition, the hairspring would lengthen, decreasing its spring constant. This problem was initially solved through the use of the compensation balance. The compensation balance consisted of a ring of steel sandwiched to a ring of brass. These rings were then split in two places.
== Research == Since 2009 the Foundation has sponsored numerous clinical trials conducted by the Waterford Institute of Technology, and has funded numerous Fellowships, the principal bequest being a Chair in Human Nutrition funded permanently by it from October 2016, the current holder being Professor John Nolan PhD.
Sources: en.wikipedia.org
Her research involves structural characterization of biopolymers using mass spectrometry-based techniques, such as liquid chromatography-mass spectrometry, thin-layer chromatography-mass spectrometry, Fourier-transform ion cyclotron resonance mass spectrometry, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, microfluidic capillary electrophoresis-mass spectrometry, and ion mobility spectrometry-mass spectrometry. She was one of the first scientists to characterize glycoconjugates with tandem mass spectrometry. Her 1988 article has been cited over two thousand times. She participated in the Human Proteome Project, the SysteMHC Atlas project, and the Minimum Information Required for a Glycomics Experiment (MIRAGE) project.
12(S)-HETE, 12(S)-HpETE, and with far less potency 12(R)-HETE reduced insulin secretion and caused apoptosis in cultured human pancreatic insulin-secreting beta cell lines and prepared pancreatic islets. TNFα, IL-1β, and IFNγ also reduced insulin secretion in cultured human pancreatic INS-1 beta cells, apparently by inducing the expression of NOX1 (NADPH oxidase 1) and thereby to the production of cell-toxic reactive oxygen species; these cytokine effects were completely dependent on 12-lipoxygenase and mimicked by 12(S)-HETE but not 12(R)-HETE. 12-lipoxygenase-knockout mice (i.e., mice genetically manipulated to remove the Alox12, i.e. 12-lipoxygenase gene, see Lipoxygenase
Anthrax disease in humans results from infection with toxin producing Bacillus anthracis strains that can be inhaled, ingested in contaminated food or drink, or obtained through breaks in the skin like cuts or scrapes. Domestic and wild animals can also be infected via inhalation or ingestion. Depending on the route of entry, disease can present initially as inhalation anthrax, cutaneous anthrax, or gastrointestinal anthrax, but eventually will spread throughout the body, resulting in death, if not treated with antibiotics. Anthrax toxin is composed of three domains: protective antigen (PA), edema factor (EF), and lethal factor (LF). EF is an adenylate cyclase that targets ATP. LF enzyme is a metalloprotease that confers the lethal phenotype associated with anthrax disease. As LF is the agent responsible for the death of infected hosts, it is classified in the group of lethal toxins.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.